ADC Therapeutics SA (ADCT) Discusses ZYNLONTA Strategy, Clinical Progress, and Sales Growth Outlook Transcript

Company Overview - ADC Therapeutics is a commercial stage company focused on antibody drug conjugates, particularly known for its CD19-directed product, ZYNLONTA [1] - ZYNLONTA is currently approved for use in the third line plus DLBCL setting, with plans to expand into earlier lines of DLBCL and indolent lymphomas [1] Clinical Studies - The LOTIS-5 study is a Phase III confirmatory trial of ZYNLONTA in combination with rituximab, with results expected in the second quarter of this year [2] - The LOTIS-7 study is investigating ZYNLONTA plus glofitamab in second line plus DLBCL, with results anticipated by the end of this year [2]